单剂量脂质体两性霉素B或米卡芬净预防性治疗侵袭性肺曲霉病中性粒细胞减少小鼠模型的疗效。
Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.
作者信息
Lewis Russell E, Albert Nathaniel D, Kontoyiannis Dimitrios P
机构信息
University of Houston College of Pharmacy, Texas Medical Center Campus, Houston, Texas 77030, USA.
出版信息
Antimicrob Agents Chemother. 2008 Nov;52(11):4178-80. doi: 10.1128/AAC.00715-08. Epub 2008 Aug 25.
Abstract
In a neutropenic murine model of invasive pulmonary aspergillosis, prophylaxis with single doses of liposomal amphotericin B or micafungin at >or=5 mg/kg of body weight improved animal survival and suppressed the lung fungal burden for up to 7 days after infection, demonstrating the potential utility of infrequent dosing with these antifungals.
摘要
在侵袭性肺曲霉病的中性粒细胞减少小鼠模型中，以≥5mg/kg体重的剂量单次给予脂质体两性霉素B或米卡芬净进行预防，可提高动物存活率，并在感染后长达7天内抑制肺部真菌负荷，这表明不频繁给药使用这些抗真菌药物具有潜在效用。
相似文献
1
Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2008 Nov;52(11):4178-80. doi: 10.1128/AAC.00715-08. Epub 2008 Aug 25.
2
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection.
J Antimicrob Chemother. 2016 Aug;71(8):2230-3. doi: 10.1093/jac/dkw111. Epub 2016 May 26.
3
Therapeutic and toxicologic studies in a murine model of invasive pulmonary aspergillosis.
Med Mycol. 2011 Nov;49(8):834-47. doi: 10.3109/13693786.2011.577822. Epub 2011 May 4.
4
Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and -resistant strains of Aspergillus fumigatus.
Int J Antimicrob Agents. 2010 Feb;35(2):146-51. doi: 10.1016/j.ijantimicag.2009.09.029. Epub 2009 Dec 16.
5
Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2009 Aug;53(8):3508-10. doi: 10.1128/AAC.00285-09. Epub 2009 Jun 15.
6
Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.
Antimicrob Agents Chemother. 2010 Sep;54(9):3884-94. doi: 10.1128/AAC.01554-09. Epub 2010 Jul 6.
7
Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
J Antimicrob Chemother. 2003 Apr;51(4):913-9. doi: 10.1093/jac/dkg185. Epub 2003 Mar 13.
8
Differences in efficacy and cytokine profiles following echinocandin or liposomal amphotericin B monotherapy or combination therapy for murine pulmonary or systemic Aspergillus flavus infections.
Antimicrob Agents Chemother. 2012 Jan;56(1):218-30. doi: 10.1128/AAC.00607-11. Epub 2011 Oct 3.
9
Prophylactic efficacy of single dose pulmonary administration of amphotericin B inhalation powder in a guinea pig model of invasive pulmonary aspergillosis.
J Antimicrob Chemother. 2012 Apr;67(4):970-6. doi: 10.1093/jac/dkr567. Epub 2012 Jan 11.
10
Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.
Antimicrob Agents Chemother. 2006 Feb;50(2):422-7. doi: 10.1128/AAC.50.2.422-427.2006.
引用本文的文献
1
Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications.
Membranes (Basel). 2022 Jun 30;12(7):681. doi: 10.3390/membranes12070681.
2
Extrapolating Antifungal Animal Data to Humans - Is it reliable?
Curr Fungal Infect Rep. 2020 Mar;14(1):50-62. doi: 10.1007/s12281-020-00370-x. Epub 2020 Jan 16.
3
Increased Efficacy of Oral Fixed-Dose Combination of Amphotericin B and AHCC Natural Adjuvant against Aspergillosis.
Pharmaceutics. 2019 Sep 3;11(9):456. doi: 10.3390/pharmaceutics11090456.
4
Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.
Clin Infect Dis. 2019 May 2;68(Suppl 4):S244-S259. doi: 10.1093/cid/ciz064.
5
Extended Dosing Regimens for Fungal Prophylaxis.
Clin Microbiol Rev. 2019 May 15;32(3). doi: 10.1128/CMR.00010-19. Print 2019 Jun 19.
6
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
Drugs. 2016 Mar;76(4):485-500. doi: 10.1007/s40265-016-0538-7.
7
Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10660-5. doi: 10.1073/pnas.1312789111. Epub 2014 Jul 7.
8
Impact of in vivo triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates.
Antimicrob Agents Chemother. 2013 Nov;57(11):5438-47. doi: 10.1128/AAC.00833-13. Epub 2013 Aug 19.
9
Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia.
Antimicrob Agents Chemother. 2013 Jun;57(6):2596-602. doi: 10.1128/AAC.00155-13. Epub 2013 Mar 25.
10
Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2013 Jan;57(1):579-85. doi: 10.1128/AAC.01279-12. Epub 2012 Nov 12.
本文引用的文献
1
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258.
2
Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Int J Antimicrob Agents. 2008 Feb;31(2):135-41. doi: 10.1016/j.ijantimicag.2007.10.001. Epub 2007 Dec 26.
3
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
Antimicrob Agents Chemother. 2008 Feb;52(2):539-50. doi: 10.1128/AAC.01061-07. Epub 2007 Dec 10.
4
High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
Bone Marrow Transplant. 2007 Mar;39(5):301-6. doi: 10.1038/sj.bmt.1705592. Epub 2007 Jan 29.
5
Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1253-8. doi: 10.1128/AAC.01449-06. Epub 2007 Jan 29.
6
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia.
Antimicrob Agents Chemother. 2007 Mar;51(3):968-74. doi: 10.1128/AAC.01337-06. Epub 2006 Dec 28.
7
Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Antimicrob Agents Chemother. 2006 Jun;50(6):2122-31. doi: 10.1128/AAC.00315-06.
8
High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Biol Blood Marrow Transplant. 2006 Feb;12(2):235-40. doi: 10.1016/j.bbmt.2005.10.010.
9
Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Antimicrob Agents Chemother. 2006 Feb;50(2):674-84. doi: 10.1128/AAC.50.2.674-684.2006.
10
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother. 2006 Feb;50(2):469-73. doi: 10.1128/AAC.50.2.469-473.2006.
Zotero 插件